Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Share-based Compensation (2018 - 2025)

Historic Share-based Compensation for 10x Genomics (TXG) over the last 8 years, with Q4 2025 value amounting to $25.2 million.

  • 10x Genomics' Share-based Compensation fell 2249.85% to $25.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $109.1 million, marking a year-over-year decrease of 2247.33%. This contributed to the annual value of $109.1 million for FY2025, which is 2247.33% down from last year.
  • According to the latest figures from Q4 2025, 10x Genomics' Share-based Compensation is $25.2 million, which was down 2249.85% from $25.3 million recorded in Q3 2025.
  • 10x Genomics' Share-based Compensation's 5-year high stood at $45.7 million during Q2 2023, with a 5-year trough of $16.2 million in Q1 2021.
  • In the last 5 years, 10x Genomics' Share-based Compensation had a median value of $33.0 million in 2022 and averaged $32.5 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first soared by 14078.59% in 2021, then tumbled by 2840.33% in 2025.
  • 10x Genomics' Share-based Compensation (Quarter) stood at $26.9 million in 2021, then surged by 52.3% to $41.0 million in 2022, then decreased by 5.02% to $38.9 million in 2023, then dropped by 16.39% to $32.5 million in 2024, then dropped by 22.5% to $25.2 million in 2025.
  • Its Share-based Compensation was $25.2 million in Q4 2025, compared to $25.3 million in Q3 2025 and $27.6 million in Q2 2025.